Although candidates like leflunomide, an inhibitor of dihydroorotate dehydrogenase, have been suggested as potential treatments for MEN1 mutation-positive tumors (17), no established chemotherapeutic regimen has proven effective for sporadic PC harboring MEN1 mutations. This evidence concerns the gene DHODH and pachyonychia congenita.